What is believed to be the first study of a nutraceutical published in a medical journal has revealed promising results for more than 10 million Americans suffering from osteoporosis and 43 million ...

CEO Mitchell Steiner stated that Veru is advancing its late-stage clinical pipeline, focusing on two oral small molecule drugs: enobosarm, a selective androgen receptor modulator for combination with ...